Carregant...
P09.22 Moderate hypofrationated accelerated radiotherapy with concurrent and/or adjuvant temozolomide using tomotherapy for patients with glioblastoma
Background: The outcome for patients with Glioblastoma (GM) still remains poor (median survival 16 months and overall survival rates 27% at 2 years). Local progression is common after radiation therapy with or without chemotherapy for GM. So, hypothesizing that a hypofrationated accelerated radiothe...
Guardat en:
| Publicat a: | Neuro Oncol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5463840/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.278 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|